STW 5 (Iberogast®)—a safe and effective standard in the treatment of functional gastrointestinal disorders

Ottillinger, Bertram; Storr, Martin; Malfertheiner, Peter; Allescher, Hans–Dieter

doi:10.1007/s10354-012-0169-x

Cited by 100 publications

(88 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in homeopathic medicine, high-dilutions (potencies) of C. majus extract have been also used to treat numerous diseases. Some C. majus containing herbal and homeopathic products are already available in the market, including Gastol TM (Ulysses Pharmaceuticals, Kolkata, India) for hyperacidity; Hepeel ® (Heel Healthcare, BadenBaden, Germany) for liver disorders; and Iberogast ® (Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany) for gastrointestinal disorders [137][138] . Recently, a semisynthetic derivative of C. majus alkaloid (chelidonine) known as Ukrain TM (Nowicky Pharma, Vienna, Austria) are commercially available to treat cancer.…”

Section: Current Drugs and Future Prospectmentioning

confidence: 99%

Chelidonium majus L. (Greater celandine) – A Review on its Phytochemical and Therapeutic Perspectives

Maji¹,

Banerji²

2015

Int. J. Herb. Med.

View full text Add to dashboard Cite

Chelidonium majus L. (Papaveraceae) is a medicinal herb used in various traditional systems of medicine to treat ulcer, cancer, oral infection, liver disorders, chronic bronchitis, asthma, etc. Different parts of this plant contain numerous therapeutically important alkaloidal constituents such as chelidonine, chelerythrine, sanguinarine, berberine and so on. The plant and its active compounds exhibit a wide range of pharmacological activities. The plants has long history of therapeutic use in medicines without any toxic effect. Today it is one of the important components of some pharmaceutical preparations. Consumption of C. majus preparations possesses toxic effects on the liver although the effect becomes controversial with its hepatoprotective effect. Numerous active constituents of C. majus interact with various drug metabolizing enzymes that mimic possible interactions of this herb with the conventional drugs. This review provides detailed phytochemical, pharmacological and toxicological information of C. majus along with mechanisms of action of its various active compounds on different aspects of pharmacology. This review also highlights plausible drug interaction of its various active compounds and the future prospect of this herb.

show abstract

Section: Current Drugs and Future Prospectmentioning

confidence: 99%

Chelidonium majus L. (Greater celandine) – A Review on its Phytochemical and Therapeutic Perspectives

Maji¹,

Banerji²

2015

Int. J. Herb. Med.

View full text Add to dashboard Cite

show abstract

“…STW 5 was well tolerated in all examined populations (including children), independent of concomitant diseases. There was no hint of STW 5 having any kind of interactions with other drugs [11, 14]. …”

Section: Safety Of Stwmentioning

confidence: 99%

STW 5 (Iberogast) Therapy in Gastrointestinal Functional Disorders

Malfertheiner¹

2017

Dig Dis

Self Cite

View full text Add to dashboard Cite

Background: Functional gastrointestinal disorders (FGIDs) are very common and affect populations worldwide. A majority of patients are affected by a variety of heterogenous gastrointestinal symptoms (GIS) related to the upper and lower digestive system with frequent overlap and mostly of mild to moderate degree. The herbal medicinal preparation STW 5 is documented as an effective therapeutic option for treating FGID. Studies Conducted in Summary: STW 5 has been in use for more than 50 years in clinical practice and proven to be effective and safe in the management of FGID. The high efficacy of STW 5 on symptoms clustered in functional dyspepsia (FD) and irritable bowel syndrome (IBS) as well as on individual abdominal symptoms is demonstrated in 5 controlled, randomized double-blind studies in FD and in one trial conducted in patients with IBS. In addition the beneficial therapeutic effect of STW 5 on FGD as well as safety issues have been reported in a series of non interventional studies conducted in several thousands of adult patients and including 980 children. An additional study has been performed addressing the question as to how quickly the therapeutic effect is obtained after STW 5 administration. Key Messages from These Studies: STW 5 is an effective phyto-medication for treating patients with FD and IBS. STW 5 acts beneficially on abdominal symptom clusters as well as on individual GIS in adults and children. The time to onset of action is rapid, well tolerated and safe. The repetitive use of STW 5 is an appropriate option in clinical practice for patients with FGID.

show abstract

“…The tolerability of STW 5 was favorable, both in clinical studies and in post-marketing use [18]. Various studies evaluated the tolerability profile of STW 5: the incidence of adverse drug reactions was 0.04%.…”

Section: Herbal Medicationsmentioning

confidence: 99%

Functional Gastrointestinal Disorders: Complex Treatments for Complex Pathophysiological Mechanisms

Mearin

Malfertheiner

2017

Dig Dis

Self Cite

View full text Add to dashboard Cite

STW 5 (Iberogast®)—a safe and effective standard in the treatment of functional gastrointestinal disorders

Cited by 100 publications

References 21 publications

Chelidonium majus L. (Greater celandine) – A Review on its Phytochemical and Therapeutic Perspectives

Chelidonium majus L. (Greater celandine) – A Review on its Phytochemical and Therapeutic Perspectives

STW 5 (Iberogast) Therapy in Gastrointestinal Functional Disorders

Functional Gastrointestinal Disorders: Complex Treatments for Complex Pathophysiological Mechanisms

Contact Info

Product

Resources

About